Payer Perspectives on Intravenous versus Subcutaneous Administration of Drugs

References

• National Home Infusion Association (NHIA). NHIA Home and Specialty Infusion Industry Recommendations for Providing Services During the COVID-19 Outbreak; 2019. Available from: https://www.nhia.org/covid-19_guidance/. Accessed 20 August 2020.
   Google Scholar
• Cinar P, Kubal T, Freifeld A, et al. Safety at the Time of the COVID-19 Pandemic: how to Keep Our Oncology Patients and Healthcare Workers Safe. J National Compreh Cancer Net. 2020;18(5):504.
   Web of Science ®Google Scholar
• Pharmaprojects. Pharma R&D Annual Review 2019; 2019. Available from: https://pharmaintelligence.informa.com/~/media/informa-shop-window/pharma/2019/files/whitepapers/pharma-rd-review-2019-whitepaper.pdf. Accessed 27 October 2020.
   Google Scholar
• Mikulic M Worldwide pipeline drugs by delivery route share 2019; 2019. Available from: https://www.statista.com/statistics/791731/share-of-pipeline-drugs-worldwide-by-delivery-route/. Accessed 2 March 2020.
   Google Scholar
• Schumock GT, Stubbings J, Hoffman JM, et al. National trends in prescription drug expenditures and projections for 2019. Am J Health Sys Pharmacy. 2019;76(15):1105–1121. doi:10.1093/ajhp/zxz109
   Web of Science ®Google Scholar
• Sanchez-Felix M, Burke M, Chen HH, Patterson C, Mittal S. Predicting bioavailability of monoclonal antibodies after subcutaneous administration: open innovation challenge. Adv Drug Deliv Rev. 2020;167:66–77. doi:10.1016/j.addr.2020.05.009
   PubMed Web of Science ®Google Scholar
• Johnson B. NDC Billing for Infusion and Injectable Medications. Available from: https://weinfuse.com/ndc-billing-for-infusion-and-injectable-medications/. Accessed 10 April 2020.
   Google Scholar
• Faust S Pharmacy vs Medical Benefit. Available from: https://www.pharmacist.com/pharmacy-vs-medical-benefit. Accessed 27 October 2020.
   Google Scholar
• Johnson B. Billing Infusion Medications. Available from: https://weinfuse.com/billing-infusion-medications/. Accessed 27 October 2020.
   Google Scholar
• Burrows SH, Akinbobuyi O, Rule S, Crosbie N. Subcutaneous rituximab can be safely administered without pre-medication. Br J Haematol. 2018;181(6):836–837. doi:10.1111/bjh.14703
   Web of Science ®Google Scholar
• Human Genome Sciences, Inc. BENLYSTA (Belimumab) [Package Insert]. Rockville, MD: Human Genome Sciences, Inc., (a subsidiary of GlaxoSmithKline); 2020.
   Google Scholar
• Schmier J, Ogden K, Nickman N, et al. Costs of Providing Infusion Therapy for Rheumatoid Arthritis in a Hospital-based Infusion Center Setting. Clin Ther. 2017;39(8):1600–1617. doi:10.1016/j.clinthera.2017.06.007
   PubMed Web of Science ®Google Scholar
• Wu N, Bhurke S, Shah N, Harrison DJ. Application of a validated algorithm to estimate the effectiveness and cost of biologics for rheumatoid arthritis in the US pharmacy benefit manager context. Clinicoecon Outcomes Res. 2015;7:257–266. doi:10.2147/CEOR.S83932
   Google Scholar
• Hansen RN, Wallick CJ, Sullivan SD. Budget Impact of the Introduction of Subcutaneous Rituximab to U.S. Health Plans. Value in Health. 2018;21:S22–S23. doi:10.1016/j.jval.2018.04.137
   Web of Science ®Google Scholar
• Tetteh EK, Morris S. Evaluating the administration costs of biologic drugs: development of a cost algorithm. Health Econ Rev. 2014;4(1):26. doi:10.1186/s13561-014-0026-2
   PubMedGoogle Scholar
• Anderson KC, Landgren O, Arend RC, Chou J, Jacobs IA. Humanistic and economic impact of subcutaneous versus intravenous administration of oncology biologics. Future Oncol. 2019;15(28):3267–3281. doi:10.2217/fon-2019-0368
   PubMed Web of Science ®Google Scholar
• Plommet N, Pau D, Tehard B. Economic Evaluation and Added Value for Stakeholders of Switching From Rituximab Intravenous Injection to Rituximab Subcutaneous Injection In France. Value in Health. 2015;18(7):A664. doi:10.1016/j.jval.2015.09.2418
   Web of Science ®Google Scholar
• Rule S, Collins GP, Samanta K. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. J Med Econ. 2014;17(7):459–468. doi:10.3111/13696998.2014.914033
   PubMedGoogle Scholar
• Olofsson S, Norrlid H, Karlsson E, Wilking U, Ragnarson Tennvall G. Societal cost of subcutaneous and intravenous trastuzumab for HER2-positive breast cancer - An observational study prospectively recording resource utilization in a Swedish healthcare setting. Breast. 2016;29:140–146. doi:10.1016/j.breast.2016.07.008
   PubMed Web of Science ®Google Scholar
• Iuliano F, Iuliano E, Rossi M. Assisted Administration of Subcutaneous Rituximab to the Patient’s Home. Significant Reduction of Indirect Costs Incurred By Care Recipients and Unpaid Caregivers Together with a Total Adherence to the Treatment Schedule and Same Safety. Blood. 2018;132(Supplement 1):5869. doi:10.1182/blood-2018-99-118756
   Web of Science ®Google Scholar
• Edo Solsona MD, Monte Boquet E, Casanova Estruch B, Poveda Andrés JL. Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart(®) in patients with multiple sclerosis. Patient Prefer Adherence. 2017;11:415–421. doi:10.2147/PPA.S127508
   PubMed Web of Science ®Google Scholar
• Bittner B, Schmit Chiesi C, Kharawala S, Kaur G, Schmidt J. Connected drug delivery devices to complement drug treatments: potential to facilitate disease management in home setting. Med Devices. 2019;12:101–127. doi:10.2147/MDER.S198943
   Web of Science ®Google Scholar
• Centers for Medicare & Medicaid Services (CMS). Physicians and Other Clinicians: CMS Flexibilities to Fight COVID-19. Available from: https://www.cms.gov/files/document/covid-19-physicians-and-practitioners.pdf. Accessed 8 October 2020.
   Google Scholar
• Lugaresi A, Rottoli MR, Patti F. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis. Expert Rev Neurother. 2014;14(9):1029–1042. doi:10.1586/14737175.2014.945523
   PubMed Web of Science ®Google Scholar
• Bayas A. Improving adherence to injectable disease-modifying drugs in multiple sclerosis. Expert Opin Drug Deliv. 2013;10(3):285–287. doi:10.1517/17425247.2013.763793
   PubMed Web of Science ®Google Scholar
• Chari A, Goldschmidt H, San-Miguel J, et al. Subcutaneous (SC) Daratumumab (DARA) in Combination With Standard Multiple Myeloma (MM) Treatment Regimens: an Open-label, Multicenter Phase 2 Study (PLEIADES). Clin Lymphoma Myeloma Leuk. 2019;19(10):e16–e17. doi:10.1016/j.clml.2019.09.023
   Web of Science ®Google Scholar
• Usmani SZ, Nahi H, Mateos MV, et al. Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma. Blood. 2019;134(8):668–677. doi:10.1182/blood.2019000667
   PubMed Web of Science ®Google Scholar
• Mateos M-V, Nahi H, Legiec W, et al. Efficacy and safety of the randomized, open-label, non-inferiority, Phase 3 study of subcutaneous (SC) versus intravenous (IV) daratumumab (DARA) administration in patients (pts) with relapsed or refractory multiple myeloma (RRMM): COLUMBA. J Clin Oncol. 2019;37(15_suppl):8005. doi:10.1200/JCO.2019.37.15_suppl.8005
   Web of Science ®Google Scholar
• Kim HJ, Yun J, Kim HJ, et al. Safety and effectiveness of central venous catheterization in patients with cancer: prospective observational study. J Korean Med Sci. 2010;25(12):1748–1753. doi:10.3346/jkms.2010.25.12.1748
   PubMed Web of Science ®Google Scholar
• Dashiell-Aje E, Harding G, Pascoe K, DeVries J, Berry P, Ramachandran S. Patient Evaluation of Satisfaction and Outcomes with an Autoinjector for Self-Administration of Subcutaneous Belimumab in Patients with Systemic Lupus Erythematosus. Patient. 2018;11(1):119–129. doi:10.1007/s40271-017-0276-2
   PubMedGoogle Scholar
• Stoner KL, Harder H, Fallowfield LJ, Jenkins VA. Intravenous versus Subcutaneous Drug Administration. Which Do Patients Prefer? A Systematic Review. Patient. 2014. doi:10.1007/s40271-014-0075-y
   PubMedGoogle Scholar
• Collins DS, Sanchez-Felix M, Badkar AV, Mrsny R. Accelerating the development of novel technologies and tools for the subcutaneous delivery of biotherapeutics. J Control Release. 2020;321:475–482. doi:10.1016/j.jconrel.2020.02.036
   PubMed Web of Science ®Google Scholar
• Vaughan LJ. Managing cost of care and healthcare utilization in patients using immunoglobulin agents. Am J Manag Care. 2019;25(6 Suppl):S105–S111.
   Google Scholar
• Ness S. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin. Am J Manag Care. 2019;25(6 Suppl):S98–S104.
   PubMedGoogle Scholar
• Rhodes RT, McFalls K A Comparative Look at IVIG and SCIG. Available from: http://www.nufactor.com/healthcare/resources/ig/articles/ar-a-comparative-look-at-ivig-and-scig.html. Accessed September 9, 2019.
   Google Scholar
• McBride A, Balu S, Campbell K, MacDonald K, Abraham I. Subcutaneous Versus Intravenous Rituximab in Non-Hodgkin Lymphoma Treated with R-CHOP: economic Modeling for the US. Blood. 2018;132(Supplement 1):4776. doi:10.1182/blood-2018-99-113283
   Web of Science ®Google Scholar
• Jang Y, Byrne A, Toron F, Yoon S Budget Impact Analysis of Intravenous Biosimilars Compared With Intravenous Originators and Subcutaneous Products. Presented at 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Conference. November 12 2018. Paper presented at: Presented at 2018 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Europe Conference. 2018; Barcelona, Spain.
   Google Scholar
• Zhang J, Xie F, Delzell E, et al. Trends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare program. Arthritis Care Res. 2013;65(11):1743–1751. doi:10.1002/acr.22055
   Google Scholar
• Pakizegee M, Stefanacci RG. Clinical pathways and policy to guard against misaligned incentives. J Clin Pathways. 2020;6(1):34–36.
   Google Scholar
• Kozma CM, Ingham M, Paris A, Ellis L. Effectiveness of step therapy policies for specialty pharmaceuticals in immune disorders. J Med Econ. 2015;18(8):646–653. doi:10.3111/13696998.2015.1035278
   PubMed Web of Science ®Google Scholar
• Ingham M, Paris A, Ellis L, Kozma C. One approach to evaluating step therapy policies for immune disorder specialty pharmaceuticals. Ann Rheum Dis. 2013;72:A564–A564. doi:10.1136/annrheumdis-2013-eular.1685
   Web of Science ®Google Scholar